Background
==========

Lung cancer is the leading cause of cancer-related deaths worldwide \[[@B1]\]. The treatment of non-small cell lung cancer (NSCLC) depends on the stage of the disease \[[@B2]\]. Lobectomy with radical lymph node dissection remains the standard initial therapy for patients with stage I, II, and IIIA NSCLC \[[@B3],[@B4]\], but limited resection has also been performed for early stage NSCLC. The Lung Cancer Study Group performed a pivotal study comparing limited resection (segment or wedge) with lobectomy for clinical stage (c-stage) IA NSCLC and found inferior overall survival and three times the local recurrence rate in the limited resection group \[[@B5]\]. Radical segmentectomy has been performed for small-sized (tumor diameter ≤3 cm) c-stage IA NSCLC \[[@B6]-[@B8]\]. In reported studies there was no significant difference in overall 5-year survival rates between patients undergoing segmentectomy compared to lobectomy (75.0 to 89.8% and 81.0 to 84.0%, respectively) \[[@B6]-[@B9]\]. In a separate study, Whitson *et al*. reported that lobectomy conferred superior unadjusted overall and cancer-specific 5-year survival compared with segmentectomy \[[@B10]\]. Thus, the issue of surgical strategy remains controversial. A phase III study is underway in Japan to evaluate overall survival of patients with small-sized (tumor diameter ≤2 cm) peripheral NSCLC treated with segmentectomy versus lobectomy (JCOG0802/WJOG4607L) \[[@B11]\].

The surgical indication for radical segmentectomy must include negative hilar and mediastinal lymph node metastases. If any diseased lymph node is found, segmentectomy should be converted to standard lobectomy. In some reports, segmentectomy was performed in patients with NSCLC (tumor diameter ≤2 cm) negative for lymph node metastasis, as confirmed by frozen-section intraoperative examination \[[@B12],[@B13]\]. However, N2 lymph node metastasis without N1 hilar or interlobar lymph node involvement (skip N2 metastasis) might be overlooked if segmentectomy is performed with frozen-section examination of hilar and interlobar lymph nodes only. It has been reported that among 275 patients with c-stage IA NSCLC who were scheduled to undergo radical segmentectomy, 15 patients (6%) had pathologically confirmed N1 or N2 disease, and 4 of these (27%) had skip N2 metastasis \[[@B14]\]. Recently, intraoperative sentinel-node biopsy has been performed using new methods, such as isotope \[[@B14],[@B15]\] or indocyanine green fluorescence \[[@B16]\] to avoid overlooking skip N2 metastasis. Patients with skip N2 have a better prognosis than non-skip N2 patients (overall 5-year survival rate, 34.4 to 41.0% and 14.0 to 24.0%, respectively) when treated with lobectomy and hilar and mediastinal lymph node dissection \[[@B17]-[@B22]\]. Therefore, accurate preoperative prediction of lymph node involvement is very important in planning adequate surgical resection. Our aim was to investigate the preoperative and intraoperative predictors of skip N2 and to recommend appropriate surgical resection in small-sized (tumor diameter ≤ 3 cm) c-stage IA NSCLC.

Methods
=======

Two hundred seventy-nine patients (155 men and 124 women, mean age 66.2 years) with c-stage IA (tumor diameter ≤3 cm) NSCLC underwent pulmonary resection (R0) at Osaka City University Hospital from January 1998 to December 2011. The surgical procedure performed was potentially curative complete resection by systematic lobectomy in combination with hilar and mediastinal lymph node dissection (over ND2a-1). When lymph node metastases in lymph nodes number 10, 11, and 12 were suspected intraoperatively, these lymph nodes were examined by frozen section. Patients with preoperative chemotherapy or radiation therapy were excluded from the study. Pathological diagnoses were performed by at least two pathologists in our hospital according to the criteria of the World Health Organization \[[@B23]\], and stages were classified according to the tumor, metastasis, node (TMN) classification of the International Union Against Cancer \[[@B24]\]. Chest and abdominal computed tomography (CT), magnetic resonance imaging (MRI) of the brain, bone scintigraphy, and positron-emission tomography (PET) were performed to examine the distant metastasis. If CT revealed a mediastinal lymph node with a short axis-length over 10 mm, mediastinal staging was performed using video-assisted thoracotomy, fine-needle aspiration with bronchoscopy, or PET. The sites of the N1 and N2 lymph nodes were determined based on primary tumor location according to the International Association for the Study of Lung Cancer using the new lymph node map for NSCLC \[[@B25]\]. Skip N2 metastases were defined as N2 lymph node metastases without N1 node involvement. Histopathologic evaluations were done by microscopic examinations of hematoxylin and eosin staining. Proportion of ground-glass opacity (GGO) area was calculated as follows:

$$\begin{array}{l}
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{\mspace{27mu}\left( /{Area}\mspace{9mu}{on}\mspace{9mu}{lung}\mspace{9mu}{window} \right) \times 100.} \\
\end{array}$$

Preoperative serum concentrations of carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1), and sialyl-Lewis X (SLX) were measured in each patient.

Institutional review board approval and informed consent
--------------------------------------------------------

This study was approved by the ethics committee at Osaka City University Graduate School of Medicine. Written informed consent was received from all patients.

Statistical analysis
--------------------

All statistical analyses were performed using GraphPad Prism, version 5 (GraphPad Software, San Diego, CA, USA) and JMP, version 9 (SAS Institute, Cary, NC, USA). Differences in serum levels of CEA, CYFRA21-1, and SLX were analyzed for statistical significance using a nonparametric test (Mann--Whitney *U*-test). Receiver operating characteristic (ROC) curve analysis was used to determine the optimal cutoff point and the sensitivity and specificity of each tumor marker to distinguish skip N2 patients from patients without pathological lymph node metastasis (pN0). The area under the ROC curve (AUC) was calculated. Statistical significance of the associations between skip N2 and various clinicopathological variables was evaluated using univariate analysis and multivariate logistic regression analysis. Survival curves were calculated from the day of surgery to death or to final follow up using the Kaplan-Meier method, and differences in survival curves were assessed with the log-rank test. *P*-values \<0.05 were considered statistically significant.

Results
=======

Postoperative survival of patients with different pathological N factors
------------------------------------------------------------------------

The 279 patients with NSCLC included 230 patients without pathological lymph node metastasis (pN0), 17 patients with hilar or interlobar lymph node metastasis (pN1), 12 patients with skip N2 metastasis, and 20 patients with non-skip N2 metastasis. Table [1](#T1){ref-type="table"} shows pathological stages of patients based on each pathological N factor. The median postoperative observation time was 47 months (range 2 to 148 months). The overall 5-year survival rates for patients with pN0, pN1, skip N2, and non-skip N2 were 86.7%, 82.4%, 78.6%, and 44.9%, respectively (Figure [1](#F1){ref-type="fig"}). The prognosis of skip N2 patients was significantly better than that of non-skip N2 patients (*P* = 0.018). There were no significant differences between the prognoses of skip N2 and pN0 or pN1 patients (*P* = 0.336, *P* = 0.700, respectively).

###### 

Pathological stages of patients based on each pathological N factor

                        **Number of patients**               
  -------------------- ------------------------ ------ ----- -----
  Pathological stage                                            
    IA/IB                       189/31           0/0    0/0   0/0
    IIA/IIB                      0/4             17/0   0/0   0/0
    IIIA                          6               0     12    20

![**Kaplan-Meier curves for postoperative overall survival of 230 pathologic (p)N0 patients, 17 pN1 patients, 12 skip N2 patients, and 20 non-skip N2 patients.** The prognosis of skip N2 patients was significantly better than that of non-skip N2 patients (*P* = 0.008). There was no significant difference between the prognosis of skip N2 and pN0 or pN1 patients (*P* = 0.801, *P* = 0.985, respectively). pN0: pathological N0; pN1: pathological N1.](1477-7819-11-309-1){#F1}

Distributions of serum CEA, CYFRA21-1, and SLX in pN0 and skip N2 patients
--------------------------------------------------------------------------

To avoid underestimating skip N2 metastasis with frozen-section examination of only hilar and interlobar lymph nodes, clinical and surgical features of pN0 and skip N2 patients were compared. Table [2](#T2){ref-type="table"} shows the mean serum concentration of CEA, CYFRA21-1, and SLX in pN0 and skip N2 patients. Serum concentrations of CEA and CYFRA21-1 were not significantly different between the two groups (*P* = 0.196, *P* = 0.936, respectively). As shown in Figure [2](#F2){ref-type="fig"}, serum concentration of SLX rose with increasing pathological N factor. The serum SLX levels in skip N2 patients (mean 28.0 U/mL) and non-skip N2 patients (mean, 33.6 U/mL) were significantly higher than in pN0 patients (mean, 22.9 U/mL; *P* = 0.015, *P* = 0.001, respectively). There was no significant difference between the serum SLX levels of pN1 (mean 25.1 U/mL) and pN0 patients (*P* = 0.226). The ROC curve of SLX concentration to distinguish skip N2 patients from pN0 patients is shown in Figure [3](#F3){ref-type="fig"}. The AUC was 0.710. The calculated optimal cutoff point for serum SLX level was 21.4 U/mL (Youden index = 0.433). The sensitivity of this cutoff was 91.7% (11 of 12 skip N2 patients), and the specificity was 51.7% (109 of 211 pN0 patients). ROC curve analysis of CEA levels was also performed. The AUC was 0.611, the optimal cutoff point was 2.8 ng/mL, and the sensitivity and specificity were 91.7% and 37.3%, respectively. There was no significant difference between the AUC of SLX and CEA (*P* = 0.227).

###### 

Serum concentrations of CEA, CYFRA21-1, and SLX in pN0 and skip N2 patients

                                                                                        **Number of patients**   **Mean serum level (95% CI)**     ***P*-value**                        
  ------------------------------------------------------------------------------------ ------------------------ ------------------------------- ------------------- ------------------- -------
  CEA (ng/mL)                                                                                    230                          12                  5.3 (4.5, 6.0)      5.4 (3.5, 7.4)     0.196
  CYFRA21-1 (ng/mL)                                                                              219                          12                  1.4 (1.3, 1.6)      1.8 (0.6, 2.9)     0.936
  SLX (U/mL)                                                                                     211                          12                 22.9 (21.7, 24.1)   28.0 (23.5, 32.6)   0.015
  CEA: carcinoembryonic antigen; CYFRA: cytokeratin 19 fragment; SLX: sialyl Lewis X                                 Mann-Whitney *U*-test                                              

![**Percentile distribution of serum sialyl Lewis X (SLX) concentrations in pathological (p)N0, pN1, skip N2, and non-skip N2 patients with clinical stage IA non-small cell lung cancer (NSCLC).** Each box contains the variable distribution between the 25th and 75th percentiles, with median value indicated with a line in the box. The bars extending above and below the box indicate the 90th and 10th percentiles, respectively. The mean SLX concentration was significantly higher in the skip N2 patients compared to that in the pN0 patients (*P* = 0.015).](1477-7819-11-309-2){#F2}

![**Receiver operating characteristic curve for serum sialyl Lewis X (SLX) in pathological (p)N0 and skip N2 patients.** The area under the curve (AUC**)** = 0.710. The calculated optimal cutoff point for serum SLX concentration was 21.4 U/mL (Youden index = 0.433), and the sensitivity was 91.7% (11 of 12 skip N2 patients), whereas the specificity was 51.7% (109 of 211 pN0 patients).](1477-7819-11-309-3){#F3}

Clinicopathological features of 12 skip N2 patients
---------------------------------------------------

Table [3](#T3){ref-type="table"} shows clinicopathological features of 12 skip N2 patients according to age, sex, tumor side, tumor location, histology, tumor size, proportion of GGO, distance from tumor to pleura on CT, serum concentration of SLX, lymph vessel invasion (ly) factor, venous invasion (v) factor, pathological pleural invasion (pPL) factor, and site of skip N2 metastasis. Of 12 patients with skip N2, 10 (83.3%) were positive for ly factor, and 5 (41.7%) were positive for v factor, whereas among pN0 patients, only 20.2% were positive for ly factor and 3.8% for v factor (*P* \<0.001). On preoperative CT, eight of twelve skip N2 patients had peripheral lung cancers located close to the pleura (distance ≤5 mm). Six patients (50%) had lung cancer in the lower lobes; of these, three had skip metastasis to subcarinal lymph nodes and three had skip metastasis to upper mediastinal lymph nodes. By contrast, all six patients with lung cancer in the upper lobes had skip metastasis to upper mediastinal lymph nodes. In relation to the site of skip N2 metastasis, nine patients (75%) had single-station disease, and three patients (25%) had multi-station disease.

###### 

Clinicopathological features of 12 skip N2 patients

  **Pt. no.**    **Age/sex**   **Side**   **Location (lobe)**   **Histology**   **Tumor size (mm)**   **Proportion of GGO (%)**   **Distance to pleura (mm)**   **SLX (U/mL)**   **ly**   **v**   **pPL**   **Site of skip N2**
  ------------- ------------- ---------- --------------------- --------------- --------------------- --------------------------- ----------------------------- ---------------- -------- ------- --------- ---------------------
  1                 73/M          Rt             Upper               Sq                 15                       19                            4                     36.2          \+      \-        0         No. 2R, 4R LN
  2                 34/F          Rt             Upper               Ad                 16                       68                           13                     27.4          \+      \-        0           No.4R LN
  3                 70/F          Rt             Upper               Ad                 21                       47                           30                     21.4          \+      \+        0         No.2R, 4R LN
  4                 62/F          Rt             Upper               Ad                 14                       24                           28                     13.1          \+      \-        0           No. 4R LN
  5                 71/M          Rt             Lower               Ad                 30                        9                            0                     40.2          \-      \-        0           No. 7 LN
  6                 61/F          Rt             Lower               Ad                 24                       27                            0                     32.8          \+      \+        1           No. 7 LN
  7                 60 M          Rt             Lower               Ad                 24                       23                            0                     29.0          \+      \+        0         No.2R, 4R LN
  8                 62/F          Lt             Upper               Ad                 20                       72                            5                     23.6          \+      \+        1           No. 5 LN
  9                 81/M          Lt             Upper               Sq                 27                       13                            0                     24.5          \+      \-        2           No. 5 LN
  10                63/M          Lt             Lower               Ad                 15                       38                            0                     28.0          \+      \-        0           No. 5 LN
  11                60/M          Lt             Lower               Ad                 23                        7                           14                     27.0          \-      \+        0           No. 7 LN
  12                57/F          Lt             Lower               Ad                 20                        3                            0                     33.0          \+      \-        0           No. 5 LN

Pt. no., patient number; M,male; F, female; Rt, right; Lt, left; Ad, adenocarcinoma; Sq, squamous cell carcinoma; GGO, ground-glass opacity; distance to pleura, measured on computed-tomography; SLX, sialyl Lewis X; ly, lymph vessel invasion factor; v, venous invasion factor; pPL, pathological pleural invasion factor; No. 2R, upper paratracheal lymph node; No. 4R LN, lower paratracheal lymph node; No. 5 LN, subaortic lymph node; No. 7 LN, subcarinal lymph node.

Clinical and surgical features of pN0 and skip N2 patients
----------------------------------------------------------

To reveal preoperative and intraoperative predictive factors for skip N2, we compared pN0 and skip N2 patients, looking for underestimation of nodal factors based on intraoperative hilar or interlobar lymph node examination. Table [4](#T4){ref-type="table"} lists the clinical and surgical features of 230 pN0 patients and 12 skip N2 patients according to age, sex, tumor side, tumor location, histology, tumor differentiation, tumor diameter, sPL factor, serum SLX concentration, and serum CEA concentration. Univariate analysis revealed that skip N2 was significantly associated with elevated serum SLX concentrations (odds ratio = 9.91; *P* = 0.007). There were no significant differences between the two groups in other clinical or surgical features. Results of multivariate analysis show that SLX was the only independent predictor of skip N2 metastasis in patients with c-stage IA NSCLC (odds ratio = 9.43; *P* = 0.006).

###### 

Clinical and surgical features of 230 pathological (p)N0 patients and 12 skip N2 patients

                                                  **Number of patients**        **Univariate**                    **Multivariate**                              
  ---------------------------------------------- ------------------------ -------------------------- ------------------------------------------- ------- ------ ------------
  Age                                                                                                                                                                 
    Mean ± SD                                          66.5 ± 10.2               62.8 ± 11.4                          0.268^a^                                        
  Sex                                                                                                                                                                 
    Male                                                   121                        6                                 1.000                      NA      NA        NA
    Female                                                 109                        6                                                                               
  Side                                                                                                                                                                
    Right                                                  131                        7                                 1.000                      NA      NA        NA
    Left                                                    99                        5                                                                               
  Location                                                                                                                                                            
    Upper/Middle lobe                                      151                        6                                 0.353                      NA      NA        NA
    Lower lobe                                              79                        6                                                                               
  Histology                                                                                                                                                           
    Ad                                                     192                        10                                1.000                      NA      NA        NA
    Sq/AdSq                                                 38                        2                                                                               
  Tumor differentiation                                                                                                                                               
    Well/moderate                                          181                        7                                 0.146                     0.361   1.80   0.49, 6.13
    Poor                                                    49                        5                                                                               
  Tumor diameter (cm)                                                                                                                                                 
    ≤2                                                     113                        6                                 1.000                      NA      NA        NA
    \>2                                                    117                        6                                                                               
  sPL factor                                                                                                                                                          
    sPL0                                                   141                        6                                 0.547                      NA      NA        NA
    sPL1-3                                                  89                        6                                                                               
  SLX (U/mL)                                                                                                                                                          
    ≥21.4                                                  121                        11                                0.007                     0.006   9.43   1.75, 175
    \<21.4                                                 109                        1                                                                               
  CEA (ng/mL)                                                                                                                                                         
    ≥2.8                                                   143                        11                                0.060                     0.077   4.78   0.87, 89.2
    \<2.8                                                   87                        1                                                                               
  Ad: adenocarcinoma                                                         Fisher's exact test      Multivariate logistic regression analysis                 
  Sq: squamous cell carcinoma                                              ^a^Mann-Whitney *U*-test                                                             
  AdSq: adenosquamous carcinoma                                                                                                                                 
  sPL factor: surgical pleural invasion factor                                                                                                                  
  CI: confidence interval                                                                                                                                       

Discussion
==========

Radical segmentectomy with systematic lymph node dissection has been performed for small-sized NSCLC \[[@B7],[@B8],[@B14],[@B15]\]. When intraoperative frozen-section examination of hilar or interlobar lymph node reveals metastasis, we believe segmentectomy should be converted to standard lobectomy. The question of whether radical segmentectomy allows adequate lymph node dissection remains controversial, because the mean number of dissected lymph nodes with segmentectomy is significantly lower than with lobectomy \[[@B7]\]. Intraoperative frozen-section examination of hilar or interlobar lymph can detect pN1 or non-skip N2 disease, which leads to appropriate surgical resection. However, underestimation of skip N2 due to the difficulty of examining all mediastinal lymph nodes intraoperatively leads to challenges in choosing the appropriate surgical procedure. In a study on intraoperative sentinel lymph node identification, Kim *et al*. reported that five of forty c-stage I NSCLC patients (12.5%) had mediastinal sentinel lymph nodes without hilar lymph node involvement \[[@B26]\]. One mechanism of skip N2 is lymphatic flow from the lung directly to the mediastinum through the pleura \[[@B27]\]. Radical segmentectomy for patients with skip N2 metastasis has the possibility that micro cancer cells remain in pleural lymphatic ducts. Therefore, a preoperative or intraoperative predictive factor for skip N2 metastasis is necessary to choose adequate surgical resection.

Skip metastasis to mediastinal lymph nodes has been reported to occur in 20 to 40% of patients with N2 NSCLC \[[@B4],[@B27],[@B28]\]. In our study, the 5-year survival rate for skip N2 patients was even higher than that in other previous reports \[[@B17]-[@B22]\], which was because these previous reports included many patients with large-sized tumor (tumor diameter \>3 cm) \[[@B18],[@B20]-[@B22]\]. In addition, 75% of skip N2 patients had single-station disease, which was more frequent than the other reports \[[@B21],[@B22]\] and affected this discrepancy. In several reports, clinicopathological factors were analyzed in patients with skip N2 metastasis. Skip N2 metastasis was more frequent with tumors in the upper lobes than the lower lobes \[[@B17],[@B18]\], in right-sided lesions than left-sided lesions \[[@B21]\], and in cases of squamous cell carcinoma than in cases of adenocarcinoma \[[@B21],[@B22]\]. In our study, there were no significant differences between pN0 and skip N2 patients in tumor side, location, or histology. Small-sized NSCLCs are heterogenous, including pure GGO, GGO with small consolidation and real consolidation. The proportion of GGO area on CT has been reported as a predictor of lymph node metastasis. There has been shown to be no lymph node metastasis in patients with c-stage IA adenocarcinoma with more than 50% proportion of GGO \[[@B29]\]. In addition, 98.7% of patients with c-stage IA NSCLC with less than 25% consolidation of the maximum tumor diameter showed pathological non-invasiveness \[[@B30]\]. In our study, the patients with c-stage IA NSCLC with more than a 75% proportion of GGO never exhibited skip N2 metastasis, and those with a 50 to 75% proportion of GGO occasionally exhibited skip N2 metastasis, as shown in Table [3](#T3){ref-type="table"}.

Pathological factors such as pleural invasion \[[@B31]\] and tumor size \[[@B18]\] have also been reported to be associated with skip N2. There were no significant associations between skip N2 metastasis and surgical or pathological PL factor or tumor diameter in this study. One mechanism of skip N2 is pleural lymphatic flow \[[@B27]\], and ly and v factors have been reported to predict lymph node metastasis in NSCLC \[[@B32]\]. Therefore, we investigated whether distance to pleura or intersegmental plane, ly factor, or v factor were important predictors of skip N2 metastasis. Our data support distance to pleura, ly factor, and v factor as risk factors for skip N2 metastasis as shown in Table [3](#T3){ref-type="table"}. Eight of twelve patients with skip N2 metastasis had peripheral lung cancers located close to the pleura (distance ≤5 mm), and eleven of twelve were positive for either ly or v factor. The only case of skip N2 that was close to the pleura and was negative for both ly and v factors was the largest tumor in the group (30 mm). Although ly and v factors were significantly associated with skip N2, it is important to note that these factors cannot be assessed preoperatively or intraoperatively. In our study, serum SLX concentration was the only useful preoperative or intraoperative test to help predict skip N2.

SLX is a carbohydrate antigen adhesion molecule that has been used as a tumor marker for carcinoma of many organs, including the lungs \[[@B33]\]. SLX plays an important role in cell-cell recognition and is therefore thought to be associated with the metastatic ability of cancer cells. In the case of lung cancer, we have reported that high serum concentrations of SLX are predictive of lymph node metastasis, postoperative recurrence, and poor prognosis in patients with NSCLC \[[@B34]-[@B36]\]. Several authors have reported that SLX is predictive of distant metastasis in patients with primary lung cancer \[[@B37]-[@B39]\]. As for other tumor markers, high serum CEA has also been reported to be a predictive factor for lymph node metastasis in patients with small-sized adenocarcinoma of the lung \[[@B40]\]. Although the AUC for SLX was 0.710, which was higher than that for CEA (0.611, *P* = 0.227) or for CYFRA21-1 (0.507, *P* = 0.106), results of multivariate logistic regression analysis showed serum SLX concentration was an independent predictive factor for skip N2 in patients with c-stage IA NSCLC. The calculated optimal cutoff point for serum SLX concentration in this study (21.4 U/mL) was lower than the accepted cutoff for cancer screening (38.0 U/mL). We propose that the prognosis cutoff value should be used to predict skip N2 metastasis rather than the diagnosis cutoff value.

Conclusions
===========

We found that serum SLX concentration was an independent predictive factor for skip N2 in c-stage IA NSCLC. Skip metastasis is common in NSCLC patients with high serum SLX, and lobectomy with complete dissection of hilar and mediastinal lymph nodes should remain the standard surgical procedure for these patients. Preoperative serum SLX levels have the possibility to change the present surgical procedure of segmentectomy for patients with c-stage IA NSCLC.
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